Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Choosing the Appropriate Treatment Strategy in CLL

December 22nd 2021

Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.

Using Noncovalent BTK Inhibitors for the Management of CLL

December 22nd 2021

Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.

Dr. Seymour on the Design of the ELEVATE-RR Trial in Relapsed/Refractory CLL

December 21st 2021

John F. Seymour, M​BBS, FRACP, PhD, discusses the design of the phase 3 ELEVATE-RR trial comparing acalabrutinib vs ibrutinib in chronic lymphocytic leukemia.

Toxicity Burden Decreased With Acalabrutinib Vs Ibrutinib in CLL

December 14th 2021

Acalabrutinib demonstrated a lower incidence of cardiovascular-related toxicities and a lower overall toxicity burden compared with ibrutinib in patients with chronic lymphocytic leukemia.

Acalabrutinib Shows Superior PFS, Safety Over Other Treatments in Relapsed/Refractory CLL

December 14th 2021

Acalabrutinib demonstrated an advantage in quality-adjusted survival compared with other treatments for relapsed/refractory chronic lymphocytic leukemia.

High-Frequency Low-Dose Acalabrutinib/Rituximab Combo Elicits 100% ORR in Frontline CLL/SLL

December 14th 2021

High-frequency low-dose acalabrutinib and rituximab represents a feasible and effective combination for the treatment of patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Ibrutinib Plus Venetoclax Induces Lower MRD Rate Vs FCR in Previously Untreated CLL

December 14th 2021

The combination of ibrutinib and venetoclax led to a lower rate of minimal residual disease compared with fludarabine, cyclophosphamide, and rituximab in patients with treatment-naïve chronic lymphocytic leukemia, according to preliminary findings from the phase 2 ERADIC trial.

Dr. Ghia on the Results From the 2-Year Follow-Up of the CAPTIVATE Study in CLL

December 13th 2021

Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.

Ibrutinib Plus FCR Shows Encouraging Activity as Time-Limited Option for Younger Patients With CLL

December 13th 2021

The addition of ibrutinib to fludarabine, cyclophosphamide, and rituximab resulted in a higher rate of complete responses with bone marrow undetectable minimal residual disease in younger, fit patients with chronic lymphocytic leukemia.

Acalabrutinib Improves PFS, Safety in Untreated CLL

December 13th 2021

Acalabrutinib, with or without obinutuzumab, induced a significant efficacy benefit for patients with treatment-naïve chronic lymphocytic leukemia compared with ibrutinib or venetoclax plus obinutuzumab, according to findings presented during the 63rd ASH Annual Meeting and Exposition.

Ibrutinib-Based Combos Improve PFS Vs Standard BR in Elderly Patients With CLL

December 13th 2021

Ibrutinib-containing combinations demonstrated continued progression-free survival benefit compared with standard bendamustine plus rituximab in elderly patients with previously untreated chronic lymphocytic leukemia.

Ibrutinib Plus Rituximab Confers Superior PFS to FCR in Previously Untreated CLL

December 13th 2021

The results also demonstrated no significant difference in overall survival benefit between the treatment groups. However, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.

Treatment Selection Could Be Informed by Cost and Time Spent on Managing Toxicity in CLL

December 13th 2021

Cost and personal time spent on managing adverse effects for treatment with ibrutinib, acalabrutinib, or venetoclax could inform decision-making strategies for treatment selection in patients with chronic lymphocytic leukemia.

Time-Limited Ublituximab/Umbralisib Plus Ibrutinib Achieves 77% uMRD Rate in CLL

December 13th 2021

The addition of ublituximab and umbralisib to ibrutinib produced deep remissions with favorable tolerability in patients with chronic lymphocytic leukemia who previously received ibrutinib and still had detectable minimal residual disease.

Phase 3 Trial Set to Evaluate Venetoclax Plus Acalabrutinib or Obinutuzumab in Treatment-Naive CLL/SLL

December 12th 2021

The combinations of venetoclax plus acalabrutinib or obinutuzumab will be evaluated in the phase 3 MAJIC trial.

Frontline and Continuous Treatment With Ibrutinib Plus Rituximab Improves Quality of Life in Patients With CLL

December 12th 2021

Quality of life improved in patients with chronic lymphocytic leukemia when treated in the frontline setting with ibrutinib-rituximab and with fludarabine, cyclophosphamide, and rituximab. Improved quality of life was also maintained during continuous therapy with ibrutinib and did not decline over time.

Real-World Efficacy of Tisagenlecleucel in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Similar to Clinical Trial Data With Improved Safety Outcomes

December 12th 2021

Real-world data of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia treated with tisagenlecleucel demonstrated similar efficacy outcomes and a more favorable safety profile compared with the ELIANA trial.

Updated Study Results Show Durable Responses in CLL After Fixed-Duration Ibrutinib-Venetoclax Based on Undetectable MRD

December 11th 2021

The use of ibrutinib plus venetoclax in the first-line setting for patients with previously untreated chronic lymphocytic leukemia continues to provide deep, durable responses, according to updated results from the MRD cohort of the phase 2 CAPTIVATE trial.

Frontline Venetoclax-Based Combos Improve uMRD Rates Vs Chemoimmunotherapy in Fit Patients With CLL

December 11th 2021

The combination of obinutuzumab and venetoclax (GVe), as well as GVe plus ibrutinib demonstrated superior rates of undetectable minimal residual disease compared with chemoimmunotherapy in fit patients with chronic lymphocytic leukemia, according to findings from the phase 3 GAIA (CLL13) trial.

Frontline Ibrutinib/Venetoclax Induces Higher MRD Clearance and Fewer Relapses in Elderly and Unfit CLL

December 11th 2021

Frontline fixed-duration treatment with ibrutinib plus venetoclax led to deeper and prolonged rates of undetectable minimal residual disease in the bone marrow and peripheral blood, leading to fewer relapses in the first year post-treatment vs chlorambucil plus obinutuzumab in elderly and unfit patients with chronic lymphocytic leukemia.